A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

This is a randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of L-citrulline versus placebo in patients undergoing surgery for congenital heart defects. Eligible patients undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment.

开始日期2022-06-29

申办/合作机构

Asklepion Pharmaceuticals LLC

NCT04852172 / Terminated临床1/2期

A Phase I/IIA Open-label Dose-Finding Study with Subsequent Double-blind, Placebo-controlled, Randomized Study of L-citrulline in Sickle Cell Disease Presenting to Emergency Department (ED) in Vaso Occlusive Crisis (VOC) in Children, Adolescents and Young Adults (6 to 21 Years)

The purpose of this study is to determine if intravenous L-citrulline can abrogate an active vaso-occlusive crisis in sickle cell disease, resulting in decreased pain, reduction or elimination of opiate usage, and reduction or elimination of hospital admission. The applicant is developing intravenous L-citrulline (Turnobi™) for treatment of sickle cell disease (SCD). The current development program targets treatment of sickle cell-associated vaso-occlusive crisis (VOC) specifically. The aim of Part 1 is to identify the optimum dose regimens for the Part 2 of the trial which is a double-blind, placebo controlled adaptive 'pick-the-winner' design. This study will allow assignment of more subjects to the better treatment arm/s based on emerging data. The study, initially, will evaluate efficacy and tolerability of incremental doses of intravenous (IV) L-citrulline (Turnobi™) in patients with SCD while receiving standard of care therapy for VOC.

开始日期2021-04-29

申办/合作机构

Asklepion Pharmaceuticals LLC

NCT04570384 / Completed临床2期

Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients with COVID-19 (SARS-CoV2) Illness. To evaluate safety and efficacy of a bolus loading dose and continuous intravenous infusion of L-Citrulline compared to placebo in patients hospitalized with COVID-19 infection (SARS-CoV-2).

开始日期2020-10-15

申办/合作机构

Asklepion Pharmaceuticals LLC

100 项与 Asklepion Pharmaceuticals LLC 相关的临床结果

登录后查看更多信息

0 项与 Asklepion Pharmaceuticals LLC 相关的专利（医药）

登录后查看更多信息

项与 Asklepion Pharmaceuticals LLC 相关的文献（医药）

2023-04-01·Contemporary clinical trials communications

Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department

Article

作者: McKinley, K W ; Kalsi, G ; Darbari, D S ; Thomas, B ; Campbell, A ; Nickel, R S ; Chamberlain, J ; Margulies, S ; Summar, M ; Berul, C ; Majumdar, S

Background:

Vaso-occlusive pain crisis (VOC) is the most frequent cause for Emergency Department (ED) visits and hospital admissions for patients with sickle cell disease (SCD). Nitric oxide plays a critical role in the pathogenesis of vaso-occlusion. The amino acid, citrulline, is the main endothelial nitric oxide booster that offers the potential to ameliorate vaso-occlusion and decrease the risk of hospitalization.

Objective:

In this two-part study, the goal of the first part is to determine the pharmacokinetic profile of intravenous (IV) l-citrulline and optimal dose for the second part of the study, which is to determine the efficacy and tolerability of the intervention in patients with SCD.

Design:

A phase I/IIA open-label dose-finding study with subsequent double-blind, placebo-controlled, randomized Study of l-citrulline in children and adolescents with SCD presenting to the ED in VOC.

Methods:

Part 1: Subjects experiencing VOC are enrolled in an open-label, ascending dose of IV l-citrulline to identify the optimum dose with endpoints of pharmacokinetic parameters, pain scores, reduction of opioid use, quality of life, proportion admitted to the hospital for treatment of pain, readmission rates, and assessment of adverse events. Part 2 of the trial is a double-blind, placebo-controlled adaptive "pick-the-winner" design to evaluate the efficacy and tolerability of IV l-citrulline in patients with SCD while receiving standard of care therapy for VOC.

Summary:

This ED based sickle cell adaptive trial will determine the optimal dose for IV citrulline and whether the intervention improves outcome as a potential novel therapy for VOC in SCD.

项与 Asklepion Pharmaceuticals LLC 相关的新闻（医药）

2023-02-19

·药融圈

创新药奇缺领域：这种冷门肾病迎来重磅新药sparsentan

▲3月15-16日生物医药创新者峰会 · 限时免费报名中注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。受政策、市场、技术等多方面因素影响，近年来，罕见病逐渐成为各大企业争相布局的领域，与之对应的“孤儿药”因其市场需求高、竞争相对较小，一度被认为是“重磅炸弹的摇篮”。罕见疾病从过去企业避之不及的冷门领域成为如今的兵家必争之地。罕见肾病迎来重磅新药前述榜单中恰恰就涉及到了一些极具潜力的罕见病治疗药物。其中，美国生物制药公司Travere Therapeutics正在开发的Sparsentan是全球首款也是目前唯一一款用于治疗罕见肾脏疾病的口服双效内皮素-血管紧张素受体拮抗剂（DEARA），选择性靶向内皮素A（ETA）受体和血管紧张素II亚型1（AT1）受体。该药目前被开发用于治疗IgA肾病（IgAN）以及局灶节段硬化性肾小球肾炎（FSGS），有望遏制疾病进展，填补治疗空白。2023年2月17日，Travere Therapeutics宣布美国FDA已加速批准FILSPARI™ (sparsentan)用于减少有快速疾病进展风险的原发性IgA肾病（IgAN）成人患者的蛋白尿，这些患者普遍尿蛋白与肌酐比值（UPCR）≥1.5 g/g。该药是目前首款也是唯一一款获批用于治疗这一疾病的非免疫抑制疗法。根据药融云数据www.pharnexcloud.com及企业公开信息，Sparsentan此前已在美国和欧盟获得治疗IgA肾病的孤儿药资格认定，并在美国获得优先审评资格。此外，欧洲药品管理局（EMA）已在2022年8月受理Sparsentan的有条件上市许可，预计将于2023年下半年做出审查决定。截图自药融云数据库为何值得关注？01 青壮年的“噩梦”● IgA肾病也称伯杰氏病（Berger’s disease），是一种罕见的进行性肾脏疾病，其特征是免疫球蛋白A（IgA）在肾脏中积聚引起肾脏炎症，破坏肾脏正常过滤机制，从而导致血尿、蛋白尿和肾功能的进行性丧失。该病是原发性肾小球肾炎最常见的类型，也是导致慢性肾脏病和终末期肾病（ESKD）的重要原因。该病高发于25~39岁，在亚洲人和白种人中更为常见，据估计IgA肾病在美国影响超10万人。约30~40%的IgA肾病患者会进展至终末期肾病。● 局灶节段硬化性肾小球肾炎（FSGS）是一种罕见的蛋白尿性肾脏疾病，是儿童和成人肾病综合征（NS）常见的原发性肾小球疾病，可引起肾脏的进行性瘢痕化，常导致终末期肾病。原发性FSGS通常影响25~30岁左右的患者。大多数患者在20~36个月内复发，30~60%的患者在5~10年内最终进展为终末期肾病，还有40%的患者在经过肾移植之后仍然复发。该病在美国影响约4万名患者。上述两种罕见肾病是肾病领域具有重大未满足需求的疾病，也是疾病管理最具挑战性的疾病之一。有研究显示，仅有19%的IgA肾病患者以及8%的FSGS得到了最佳的疾病管理。当前的治疗方案主要是对症治疗，通常将糖皮质激素与肾素-血管紧张素-醛固酮系统抑制剂（RAASIs）进行联用，但这些疗法常带来严重副作用。因此亟需安全、有效、耐受性好的药物来保护肾脏功能或减缓肾小球滤过率（GFR）的进行性下降。02 首款双效拮抗剂临床前数据表明，阻断ETA和AT1通路可以在罕见慢性肾脏疾病，如IgA肾病（IgAN）和局灶节段硬化性肾小球肾炎（FSGS）中减少蛋白尿，保护足细胞，并防止肾小球硬化。针对IgA肾病，Travere Therapeutics围绕Sparsentan开展的关键3期PROTECT试验是迄今为止最大的IgAN领域头对头干预性研究。公司此前已在2021年8月16日公布积极中期数据。与阳性对照厄贝沙坦（Irbesartan，血管紧张素II受体拮抗剂）治疗组相比，治疗36周后，Sparsentan治疗组患者蛋白尿水平比基线减少了3倍以上。公司当日股价上涨超15%。而对于局灶节段硬化性肾小球肾炎（FSGS），公司开展了关键3期DUPLEX试验，并于2021年2月2日公布积极中期数据。与阳性对照厄贝沙坦组（26%）相比，治疗36周后，Sparsentan组患者达到部分缓解的比例显著增加（42%）。FSGS部分缓解终点（FPRE）定义为尿蛋白与肌酐比值（UP/C）≤1.5 g/g，且UP/C比基线降低40%以上。公司当日股价上涨超11%。对于IgA肾病，美国FDA此前加速批准了Calliditas Therapeutics的TARPEYO（布地奈德）缓释胶囊，并于2022年Q1推向市场。不过作为首款获批用于治疗IgA肾病的非免疫抑制疗法获批，如果Sparsentan的试验数据最终能够证明其对肾功能的保护作用，那它或将比TARPEYO更具优势。如果这两种适应症都获得批准，Sparsentan将可能是市场上首款针对IgA肾病和FSGS都有效的治疗方法。基于中期分析结果，Travere Therapeutics早前于2022年上半年向美国FDA递交Sparsentan的加速批准申请，用于治疗IgA肾病。不过在2022年10月，公司宣布FDA要求公司更新其拟议的药品风险评估和减轻策略（REMS），将Sparsentan的肝脏监测包含在其中，从而与某些已获批的内皮素受体拮抗剂产品保持一致。因此该药原先定于2022年11月17日的PDUFA日期延后3个月至2023年2月17日。03 许可与合作值得一提的是，Sparsentan由Travere Therapeutics（当时称为Retrophin）在2012年引进自美国制药公司Ligand Pharmaceuticals，后者是license-out模式的典型代表。根据协议，Ligand获得100万美元的预付款，并可根据临床和监管进展获得超过7500万美元的里程碑付款，以及基于未来产品销售额的9%的特许权使用费。2021年9月，Travere Therapeutics与血制品巨头CSL旗下的Vifor Pharma公司达成许可协议。根据协议，Vifor获得Sparsentan在欧洲、澳大利亚和新西兰的独家商业化权利，Travere获得5500万美元的预付款，并有资格获得1.35亿美元的监管和市场准入里程碑付款，除此之外还可获得商业化里程碑和基于净销售额的分层特许权使用费。Travere专注罕见疾病Travere Therapeutics（NASDAQ GS: TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人群研发改变生命的疗法。该公司针对具有重大未满足医疗需求的罕见疾病，创建了包含多个后期临床项目的创新管线。除前文提到的核心资产Sparsentan之外，Travere还拥有2款处于临床阶段的候选产品。01 临床阶段项目Pegtibatinase（TVT-058）是一款在研的新型酶替代疗法，来自于公司在2020年11月收购的Orphan Technologies。Travere正在将其开发用于治疗经典型高胱氨酸尿症（HCU）。该病是罕见的常染色体隐性遗传病，由胱硫醚β合成酶（CBS）基因突变引起，导致CBS活性缺失，同型半胱氨酸（Hcy）代谢分解异常，从而在体内累积，可引起视力、骨骼、循环和中枢神经系统并发症。25%的HCU患者在16岁前出现血栓栓塞事件，在29岁前出现概率为50%。据估计，在美国至少有3500名HCU患者。目前尚无针对该病遗传学病因的治疗方法获批。Pegtibatinase是一款经聚乙二醇化修饰的重组人CBS酶替代疗法，有潜力成为治疗经典HCU的首款疾病修正治疗（DMT）药物。药融圈旗下药融云数据www.pharnexcloud.com显示，Pegtibatinase已被美国FDA授予罕见儿科疾病用药认定、快速通道资格、突破性疗法称号，并获得了美国和欧盟授予的孤儿药资格认定。截图自药融云数据库2021年12月，Travere公布了针对Pegtibatinase开展的1/2期COMPOSE试验的积极顶线结果。在12周的治疗期间内，患者总同型半胱氨酸（tHcy）水平呈剂量依赖性降低。最高剂量组按每次1.5mg/kg，每周两次Pegtibatinase治疗，可使总同型半胱氨酸（tHcy）水平在12周内快速持续降低，相对基线平均降低55.1%，并将tHcy维持在100μmol的临床意义阈值以下。Travere预计将在2023年第四季度启动Pegtibatinase的3期试验。除此之外，Travere生产的胆结石治疗药物Chenodal（鹅去氧胆酸，CDCA）在30多年来一直被认为是脑腱黄瘤病（CTX）的标准治疗药物，但目前该适应症尚未获得监管批准。Travere开展了一项关键3期临床以评估Chenodal在成人和儿童CTX患者中的疗效，从而支持向FDA提交Chenodal用于CTX的NDA申请。2022年9月，FDA授予Chenodal治疗CTX的快速通道资格。该药来自于公司在2014年收购的Manchester Pharmaceuticals。2023年预期里程碑：02 临床前研究针对临床前研究，Travere正在与美国国立卫生研究院的国家转化科学推动中心（NCATS）和患者组织Alagille综合征联盟合作，旨在识别治疗Alagille综合征（ALGS）的潜在小分子疗法。Alagille综合征是一种累及多系统的显性遗传性疾病，患者肝内胆管发育不良，是具有表型特征的慢性胆汁淤积的最常见原因。目前还没有治疗ALGS的药物获批。同时，据披露，公司已不再针对NGLY1缺乏症开展小分子治疗药物项目。03 已获批上市产品● Thiola（硫普罗宁）用于治疗胱氨酸尿症，公司在2014年从私人持有的Mission Pharmacal收购了该药在美国和加拿大的权利。2019年推出肠溶片剂Thiola EC（硫普罗宁片）。● Cholbam（胆酸胶囊）用于治疗因单一酶缺乏而导致的胆汁酸合成障碍，以及过氧化物酶体生物合成障碍（齐薇格谱系障碍）的辅助治疗。该药由公司在2015年收购自Asklepion Pharmaceuticals。● Chenodal（鹅去氧胆酸，CDCA）用于治疗可透过射线的胆囊结石，并被作为脑腱黄瘤病（CTX）的标准治疗药物（该适应症尚未获得监管批准）。该药来自于公司在2014年收购的Manchester Pharmaceuticals。从Retrophin到Travere由上述产品管线可以看出，Travere Therapeutics当前产品组合皆为收购得来。该公司先前名为Retrophin，专注于严重罕见疾病药物，公司前CEO是争议人物Martin Shkreli，当时他利用Retrophin频繁收购老药并提高药价，此举使得他成为“全美最招恨的人”。2014年，Retrophin董事会将Martin Shkreli解雇并在2015年对他提起诉讼。2017年，Martin Shkreli因证券欺诈罪被判入狱7年。2022年，联邦法院裁定其终身禁入制药行业。Martin Shkreli离开公司后，Retrophin继续以其专业性和科学实力维护其在生物医药领域的地位。2020年11月，公司宣布更名为Travere Therapeutics，反映了公司坚定不移地致力于帮助患者应对罕见病的生活，并与患者一起开辟新的道路，带来希望和创新，并以此纪念公司的卓越发展。目前公司战略：专注于具有严重未满足医疗需求的罕见疾病治疗药物开发采取严格的决策标准以评估潜在in-licensing候选药物，从而建立可持续发展的产品管线建立加强商业化能力，有效支持产品的商业推出倾听患者声音支持早期诊断财务业绩2021全年Travere Therapeutics公司总收入为2.275亿美元，包括2.108亿美元的产品净销售额（+6%）和1670万美元的授权与合作收入。全年研发费用为2.103亿美元，销售、一般及行政开支为1.499亿美元，总运营开支为3.893亿美元。按照产品划分，公司全年硫普罗宁产品（Thiola和Thiola EC）业绩为1.151亿美元，胆酸产品（Chenodal和Cholbam）业绩为9565万美元。2022年前三季度公司总收入为1.562亿美元，包括1.482亿美元的产品净销售额（-5%）和796.7万美元的授权与合作收入。前三季度研发费用为1.755亿美元，销售、一般及行政开支为1.573亿美元，总运营开支为3.559亿美元。公司前三季度胆酸产品业绩为7603万美元，硫普罗宁产品业绩为7215万美元。公司预计2022全年产品净销售额约为2.01亿美元。截至2022年第三季度，公司拥有现金、现金等价物和有价证券总计5.063亿美元。此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场参考：NMPA/CDE；药融云数据，www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露（除标注外，正文图片均来自企业官方）；https://ir.travere.com/；https://clarivate.com/drugs-to-watch/drugs-to-watch-listing/sparsentan/；https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy；https://www.calliditas.se/en/calliditas-therapeutics-announces-commercial-availability-and-initial-sales-of-tarpeyo/；https://ir.travere.com/news-releases/news-release-details/ligand-licenses-dara-program-retrophin；https://www.viforpharma.com/us/vifor-pharma-and-travere-therapeutics-announce-licensing-agreement-commercialization-sparsentan#；https://www.fiercebiotech.com/biotech/retrophin-announces-acquisition-of-exclusive-right-to-purchase-cholic-acid-from-asklepion；https://www.benzinga.com/government/21/11/23904774/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro；等等。线下活动（点击即可查看）点分享点点赞点在看

孤儿药优先审批临床结果免疫疗法上市批准

2021-03-15

·GlobeNewswire

Emerging Drugs for the Acute Lung Injury Treatment: A Focus

Los Angeles, USA, March 15, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Acute Lung Injury Treatment: A Focus on Recent Clinical Trials A multitude of Clinical Trials Explore Acute Lung Injury Treatments as many dominant players such as Apeiron Biologics, Asklepion Pharmaceuticals, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals, and others are developing therapies. DelveInsight’s “Acute Lung Injury Pipeline Insight'' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Acute Lung Injury pipeline landscapes. It comprises Acute Lung Injury pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Lung Injury therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Lung Injury pipeline products. Some of the significant features of the Acute Lung Injury Pipeline Report Get an overview of pipeline landscape @ Acute Lung Injury Clinical Trial Analysis Acute Lung Injury is a lung inflammation that develops in response to various pulmonary and generalized acute diseases. Acute Lung Injury Treatment is based on both ventilatory and non-ventilatory strategies. To date, the most significant advances in the supportive care of lung injury patients have been associated with improved ventilator management. Several clinical trials have shown that many pharmacologic strategies have not been effective in reducing mortality. Recent advances in understanding Acute Lung Injury pathophysiology have led to investigations of numerous potential pharmacologic treatments. Acute Lung Injury Emerging Drugs For further product profiles, request @ Acute Lung Injury Pipeline Therapeutics Scope of Acute Lung Injury Pipeline Drug Insight Key Questions regarding Current Acute Lung Injury Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get customized pipeline report @ Acute Lung Injury Drugs Pipeline Report Related Reports DelveInsight's Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast 2030 report provides a detailed overview of the disease and an understanding of historical epidemiology. DelveInsight's Acute Renal Failure (ARF)- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Tinea Pedis - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Trichotillomania- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. DelveInsight’s Athlete’s foot-Market Insights, Epidemiology and Market Forecast-2030 report deliver an in-depth understanding of the Athlete’s foot, historical and forecasted epidemiology. DelveInsight's Urothelial Carcinoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Follicular Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical l and forecasted epidemiology. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

合作

2021-02-09

·BioSpace

Asklepion Pharmaceuticals LLC announces AWINSA Life Sciences as its Clinical safety and Pharmacovigilance Service provider for their clinical trials in their fight against COVID-19

PRINCETON, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AWINSA Life Sciences, a Pharmacovigilance and Clinical Safety service provider announced that it has been selected as the preferred vendor for clinical safety management by Asklepion, a biopharmaceutical company for their upcoming trials. CMO Asklepion, Dr. Gurdyal Kalsi said, “We are very fortunate that we got this golden opportunity to contribute to the resolution of COVID-19 crisis. For this venture, we are excited to enter into a strategic alliance with AWINSA Life Sciences for clinical safety management, a team of intellectuals known for their proficiency in Pharmacovigilance and Clinical Safety.” “We are delighted to be a part of this project and our team of knowledgeable, experienced and exceptionally astute professionals will definitely give value addition to these important trials,” said Dr Sanjeev Miglani Founder and Director, AWINSA. The Co-Founder and Director of AWINSA, Dr Mugdha Chopra very rightly mentioned, “To overcome this nuanced and complicated COVID-19 crisis, the power of HOPE needs to be fuelled with scientific and authentic research. Asklepion has taken one step forward in this direction and we feel privileged to be a part of their prestigious trials.” About Asklepion Asklepion is a biopharmaceutical company based in Baltimore, Maryland. Asklepion Pharmaceuticals is dedicated to improving patients’ lives by identifying, developing and commercializing medicines which address unmet medical needs. They focus on the development of treatments for rare paediatric diseases. Asklepion strives to channel the powers of science and biotechnology into therapies that are lifesaving and to significantly improve the quality of life for sick children and anxious parents. They are led by team of seasoned executives who enrich the company with their extensive experience in various arenas. About AWINSA AWINSA is a service provider which provides end to end pharmacovigilance, medical information, medical writing and medical affairs services to Pharmaceutical and Biotech companies globally. Armed with wisdom and dedication, AWINSA aims to metamorphosize the pharmacovigilance world. The team has rock solid foundation of academics topped with sharp clinical acumen and expertise making them adept for this field. AWINSA has operations across the US, Europe and Asia. Contact information: Sanjeev Miglani, MD Director AWINSA Life Sciences info@awinsals.com +13152744862 59 E, Shrewsbury Place, Princeton, NJ 08540

合作

100 项与 Asklepion Pharmaceuticals LLC 相关的药物交易

登录后查看更多信息

100 项与 Asklepion Pharmaceuticals LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

瓜氨酸	血管闭塞危机更多	临床1期
L-Citrulline	先天性心脏缺损更多	无进展
Muscular dystrophy gene therapy(Asklepion Pharmaceuticals LLC) ( mini-dystrophin )	杜氏肌营养不良症更多	无进展